Figure 4.
Figure 4. The CYP3A4 inhibitor clarithromycin reversed the stromal-mediated FLT3 TKI resistance of FLT3/ITD AML cells. Clonogenic recovery of MV4-11 (A) and Molm14 (B) cells when cultured without (Liq) or with F/STRO (Stro) and without or with clarithromycin (+Cla) after treatment with 3 different FLT3 TKIs (20 nM sorafenib, 0.5 nM quizartinib, and 20 nM gilteritinib) for 72 hours. Data are the mean ± SEM of 3 to 4 independent experiments. *P < .05, **P < .01.

The CYP3A4 inhibitor clarithromycin reversed the stromal-mediated FLT3 TKI resistance of FLT3/ITD AML cells. Clonogenic recovery of MV4-11 (A) and Molm14 (B) cells when cultured without (Liq) or with F/STRO (Stro) and without or with clarithromycin (+Cla) after treatment with 3 different FLT3 TKIs (20 nM sorafenib, 0.5 nM quizartinib, and 20 nM gilteritinib) for 72 hours. Data are the mean ± SEM of 3 to 4 independent experiments. *P < .05, **P < .01.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal